RedHill Biopharma (RDHL) Net Cash Flow (2012 - 2022)

RedHill Biopharma (RDHL) has 11 years of Net Cash Flow data on file, last reported at -$2.4 million in Q4 2022.

• Net Cash Flow for Q4 2022 came in at -$2.4 million, down 189.24% year-over-year; the trailing twelve-month figure through Dec 2023 was -$2.4 million (up 87.4% YoY), and the FY2025 annual result was $121000.0, up 112.09% from the prior year.
• Net Cash Flow grew to -$2.4 million in Q4 2022 per RDHL's latest filing, from -$6.0 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $48.5 million in Q1 2020 and troughed at -$59.4 million in Q2 2020.
• A 5-year average of -$1.4 million and a median of -$5.4 million in 2020 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2020 and 2021: Net Cash Flow jumped 727.8% in 2020, then tumbled 818.99% in 2021.
• A 5-year view of Net Cash Flow shows it stood at $10.2 million in 2018, then surged by 118.77% to $22.2 million in 2019, then tumbled by 121.43% to -$4.8 million in 2020, then jumped by 156.96% to $2.7 million in 2021, then slumped by 189.24% to -$2.4 million in 2022.
• Business Quant data shows RDHL's Net Cash Flow at -$2.4 million in Q4 2022, -$6.0 million in Q3 2022, and -$1.7 million in Q2 2022.